Jamesi Novum

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jamesi Novum, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Jamesi Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jamesi Novum is used in the treatment of disorders related to impaired glucose regulation, primarily type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels. Adjunct to diet and exercise: enhances overall glycaemic control when metformin alone is insufficient. Combination therapy with other antidiabetics: provides additional HbA1c reduction in patients requiring multi‑drug regimens.

Jamesi Novum may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Metallic taste: altered taste sensation. - Headache: mild to moderate. - Decreased appetite: reduced food intake.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzymes. - Renal impairment: worsening kidney function.

Before prescribing Jamesi Novum, clinicians should consider several safety factors.

Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. Hepatic function monitoring: check liver enzymes periodically. Risk of lactic acidosis: contraindicated in patients with conditions predisposing to hypoxia. Hypoglycaemia monitoring: especially when used with insulin or sulfonylureas. Cardiac failure caution: avoid in uncontrolled heart failure. Pregnancy and lactation: safety not established; use only if benefits outweigh risks. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Jamesi Novum can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with iodinated contrast agents: may precipitate renal dysfunction. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase Sitagliptin exposure. - Co‑administration with other agents that increase lactic acidosis risk (e.g., alcohol excess).

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may affect renal clearance of Metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Beta‑blockers: may mask hypoglycaemia symptoms; observe blood glucose closely.